trial · primary record
Crovalimab
Atypical Hemolytic Uremic Syndrome
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 83 |
| Primary completion | 2029-08-20 |
| Primary endpoint | Naive Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25 |
| Registry ID | NCT04861259 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:43:23.330Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04861259
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.